Microbiome

An average person contains 30 trillion human cells, but even more microbes – about 39 trillion. In addition, there are possibly ten times that number of viral particles in the human virome. Understanding an individual’s microbiome is becoming increasingly important for diagnosing a broad range of diseases.

Patents that relate to the microbiome often need to be drafted differently from patents covering small molecule drugs or conventional diagnostics. For instance, some inventions lie in a way of affecting or detecting a heterogenous population of microbial cells. The cells could be defined in various ways, such as by their function or by their degree of genetic relatedness to a reference organism. Other inventions lie in a way of assessing the impact of the heterogenous population of microbes on drug metabolism, which might require functional definitions and/or specific assays to be written into the claims.

Applicants for microbiome-based patents need to be aware of legal obstacles in certain jurisdictions that would make certain claims very difficult to obtain. At Mewburn Ellis LLP, our world class training and broad experience makes us an excellent choice to be your creative, trusted advisors in this rapidly developing space.

To find out more, view our spotlight page here.

Open pages of EPO Opposition Trends in the Life Sciences Sector

Opposition Trends in the Life Sciences Sector

Special Report

In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.

View the 2020 addendum for this report, based on information as it appeared on the EPO Register on 10 January 2021 and from bulk data sets extracted on this date.

Download the Report

Read our Blogs

Gene Therapy and Longevity: Transforming the Future of Healthy Aging

Gene Therapy and Longevity: Transforming the Future of Healthy Aging

by Katherine Collins

Building on the success of gene therapies in treating rare diseases, the field is now rapidly evolving into a cornerstone of longevity science. By targeting the biological mechanisms of aging at the ...

5 reasons intellectual property is important for food-tech start-ups

5 reasons intellectual property is important for food-tech start-ups

by Nick Sutcliffe

Many food-tech start-ups we speak with say they're not too concerned about intellectual property. However, we always emphasize its importance. Here are five key reasons why we believe it deserves ...

A Boost for Sustainable Agriculture: The Promise of the US “Plant Biostimulant Act”

A Boost for Sustainable Agriculture: The Promise of the US “Plant Biostimulant Act”

by Ben Tolley

In a welcome development for sustainable agriculture, United States Representatives Jimmy Panetta (CA-19) and Jim Baird (IN-04) have introduced the Plant Biostimulant Act of 2025; a bipartisan ...

New treatments for women’s pain

New treatments for women’s pain

by Fay Allen

In a previous blog we discussed the gender pain gap and how attitudes and access to treatment of women’s pain is harming women. Unfortunately, even if women’s pain is believed by their healthcare ...

Why women’s health is such a pain: the gender pain gap

Why women’s health is such a pain: the gender pain gap

by Fay Allen

Many women’s health conditions are associated with pain, for example dysmenorrhea (period pain), endometriosis, adenomyosis, interstitial cystitis (IC), vulvodynia, chronic pelvic pain, UTIs and ...

Couriers for Cures: The Next Generation of Delivery Methods for Gene Therapy

Couriers for Cures: The Next Generation of Delivery Methods for Gene Therapy

by Katie Dale

A record number of gene therapies achieved regulatory approval in 2024, transforming how biopharma companies treat and potentially cure certain diseases. However, the forecast for gene therapy in ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.